London, 15 March 2018Autolus Limited, a UK-based biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, is pleased to be part of the Northern Alliance Advanced Therapies Treatment Centre (NAATTC) consortium and to support the Innovate Manchester Advanced Therapy Centre Hub (iMATCH) consortium, each of which have been awarded a £7 million grant from Innovate UK, the government’s innovation agency, pursuant to the £146 million Industrial Strategy Medicines Manufacturing Challenge. This funding from Innovate UK is intended to help facilitate the development, potential commercialisation and implementation of cell, gene and tissue engineered therapies in the United Kingdom.The grants, announced earlier this week by The Rt Hon Greg Clark, Secretary of State for Business, Energy and Industrial Strategy, will support the funding of a network of advanced therapies treatment centres (ATTC) in the United Kingdom, coordinated by the Cell and Gene Therapy Catapult, that will work with collaborators such as Autolus to address issues relating to the development, manufacture and supply, evaluation, funding and adoption of this new generation of potential therapies with the aim of increasing the capacity of the National Health Service (NHS) to deliver advanced therapies to patients.Dr Christian Itin, CEO of Autolus Limited, commented:
“We are delighted to collaborate with our partners in the NAATTC and to support the iMATCH consortium, and look forward to continuing to work together and share expertise to aid NAATTC’s goal of facilitating the development of advanced therapies, such as our programmed T cell product candidates, which have potential as treatment options for patients with few or no alternatives. We are grateful for the support and foresight of the UK government and Innovate UK in recognising the potential of this type of therapy by investing early in the necessary infrastructure to facilitate development of these products and adoption within the NHS, and providing the right environment for UK companies, such as Autolus, to remain at the forefront of innovation in this exciting field.”
- Ends -Media ContactJW CommunicationsJulia Wilson+44 (0)7818 430877juliawilsonuk@gmail.com
Autolus is a private, clinical-stage, biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells.For further information, please visit the Company’s website at: www.autolus.com.
The Northern Alliance is a partnership between advanced therapies companies, universities and the NHS, covering the North of England and the whole of Scotland.The Northern Alliance Advanced Therapies Treatment Centre partners are:Autolus, Chiesi Ltd, Cell Medica, Asymptote (part of GE Healthcare), Roslin Cell Therapies, Datatrial, TrakCel, Alcyomics, World Courier, Fisher BioServices (part of Thermo Fisher Scientific), Miltenyi Biotec, Newcastle upon Tyne Hospitals NHS Foundation Trust, the Scottish National Blood Transfusion Service, the Leeds Teaching Hospitals NHS Trust, NHS Lothian, NHS Greater Glasgow and Clyde, NHS Blood and Transplant, The Academic Health Science Network for the North East and North Cumbria, Newcastle University and the University of Edinburgh.
The iMATCH consortium consists of The Christie, The University of Manchester (including input from Cancer Research UK Manchester Institute and Manchester Cancer Research Centre), Manchester University NHS Foundation Trust (including Royal Manchester Children’s Hospital and Manchester Royal Infirmary) and nine life sciences-focused businesses.The nine businesses in the iMATCH consortium all have specific expertise in different aspects of delivering advanced therapies. They are AgenTus Therapeutics, Aptus Clinical, AstraZeneca (iDecide Programme), Asymptote (part of GE Healthcare), Chaucer Life Sciences, Cellular Therapeutics, The Christie Pathology Partnership, Datatrial and Formedix.
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 120 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialize these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK.
Innovate UK is the UK's innovation agency. Taking a new idea to market is a challenge. Innovate UK funds, supports and connects innovative businesses through a unique mix of people and programmes to accelerate sustainable economic growth. For further information, visit: www.innovateuk.org.Source: https://www.autolus.com/news-and-events/press-releases/autolus-support-uk-network-advanced-therapies-treatment-centres
Lorem ipsum dolor sit amet, consectetur adip elit. Donec posuere dolor massa, pellentesque aliquam nisl facilisis sed.
